It seems you are a new investor here. Just a background on Lympro..It was supposed to be CLIA approved in 2015 and corner significant portion of $150 million RUO market. GC was supposed to give revenue guidance by end of summer in 2015. These are his words. Check out his blogs from that time frame. He was touting Lympro as the gold standard last year and now it's ESS. Even Dr. Rubenfield (Amgen Co founder) lied when he said "we are there" suggesting revenue is close. I understand that clinical stage company will require funds for trials, but lying to shareholders is downright unethical and GC/BOD should be held accountable. Majority here have lost 5 figures and some 6 figures..so do your research. GC's blogs from last 2 years would be a great fairytale read.
News 
Market Data 
Discover 
